Full Press Release Details
ALTERITY THERAPEUTICS
or other type of issue
number of +securities proposed to be issued for a placement or other type of issue
| ASX +security code | +Security description | Maximum Number of +securities to be issued | |||
| New class-code to be confirmed | Options with exercise price of $0.028 and 2 year expiry | 1,212,121,212 | |||
| ATH | ORDINARY FULLY PAID | 3,636,363,636 |
page for full details of the announcement
Entity and announcement details
THERAPEUTICS LIMITED
(the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of
the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing
the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation
of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing
Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance
with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for
| 1.2 Registered Number Type | Registration Number | ||
| ABN | 37080699065 |
Date of this announcement
The Proposed issue is:
placement or other type of issue
Details of proposed placement or other issue
Do any external approvals need to be obtained or other conditions satisfied before the placement or other type of issue can proceed on
an unconditional basis?
| Approval/Condition | Date for determination | Is the date estimated or actual? | ** Approval received/condition met? | ||||
| +Security holder approval | 27/3/2025 | Estimated |
of +securities proposed to be issued
+security code and description
: ORDINARY FULLY PAID
of +securities proposed to be issued
the +securities proposed to be issued being issued for a cash consideration?
| In what currency is the cash consideraton being paid? | What is the issue price per +security? | ||
| AUD - Australian Dollar | AUD 0.01100 |
these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?
the proposed attaching security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class'
(additional +securities in a class that is already quoted or recorded by ASX)?
+Security - New class (+securities in a class that is not yet quoted or recorded by ASX)
of attaching +securities proposed to be issued
Code (if Issuer is a foreign company and +securities do not have +CDIs issued over them)
| Have you received confirmation from ASX that the terms of the proposed +securities are appropriate and equitable under listing rule 6.1? | Will the entity be seeking quotation of the 'new' class of +securities on ASX? | ||
| No | Yes |
| ASX +security code | +Security description | ||
| New class-code to be confirmed | Options with exercise price of $0.028 and 2 year expiry |
of +securities proposed to be issued
the +securities proposed to be issued being issued for a cash consideration?
Please describe the consideration being provided for
provide an estimate of the AUD equivalent of the consideration being provided for the +securities
all the +securities issued in this class rank equally in all respects from their issue date?
| Exercise price | Expiry date | ||
| AUD 0.0280 | 26/2/2027 |
of the type of +security that will be issued if the option is exercised
: ORDINARY FULLY PAID
Number of securities that will be issued if the
provide a URL link for a document lodged with ASX setting out the material terms of the +securities proposed to be issued or provide
the information by separate announcement.
Proposed +issue date
Listing Rule requirements
Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1?
Are any of the +securities proposed to be issued without +security holder approval using the entity's 15% placement capacity under listing
7D.1b ( i ) How many +securities are proposed to
be issued without security holder approval using the entity's 15% placement capacity under listing rule 7.1?
Are any of the +securities proposed to be issued without +security holder approval using the entity's additional 10% placement capacity
under listing rule 7.1A (if applicable)?
7D.1c ( i ) How many +securities are proposed to
be issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A?
( ii ) Please explain why the entity has chosen to do a placement rather than a +pro rata issue or an offer under a +security purchase
plan in which existing ordinary +security holders would have been eligible to participate
Is a party referred to in listing rule 10.11 participating in the proposed issue?
Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules?
Will any of the +securities to be issued be subject to +voluntary escrow?
Will there be a lead manager or broker to the proposed issue?
7E.1a Who is the lead manager/broker?
What fee, commission or other consideration is payable to them for acting as lead manager/broker?
Is the proposed issue to be underwritten?
7E.4 Details of any other material fees or costs
to be incurred by the entity in connection with the proposed issue
7F.01 The purpose(s) for which the entity is issuing
Will the entity be changing its dividend/distribution policy if the proposed issue proceeds?
7F.2 Any other information the entity wishes to
provide about the proposed issue
Any on-sale of the +securities proposed to be issued within 12 months of their date of issue will comply with the secondary sale provisions
in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:
publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f)